{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:06:40Z","timestamp":1783343200656,"version":"3.54.6"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"DOI":"10.7759\/cureus.70089","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:48:47Z","timestamp":1727182127000},"source":"Crossref","is-referenced-by-count":4,"title":["Immune Checkpoint Inhibitors and Endocrine Disruption: A Case of Hyponatremia and Adrenal Insufficiency"],"prefix":"10.7759","author":[{"given":"Shashwat","family":"Kafley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silbin","family":"Tamrakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Samra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya","family":"Shanmugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun DJ","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017, 13:195-207. 10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2661","article-title":"Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis","volume":"8","author":"Lu J","year":"2019","unstructured":"Lu J, Li L, Lan Y, Liang Y, Meng H. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis. Cancer Med. 2019, 8:7503-15. 10.1002\/cam4.2661","journal-title":"Cancer Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15465","article-title":"Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event","volume":"13","author":"Doodnauth AV","year":"2021","unstructured":"Doodnauth AV, Klar M, Mulatu YS, Malik ZR, Patel KH, McFarlane SI. Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event. Cureus. 2021, 13:e15465. 10.7759\/cureus.15465","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41049","article-title":"Pembrolizumab-induced adrenal insufficiency presenting eight months after cessation of treatment","volume":"15","author":"Zilberman S","year":"2023","unstructured":"Zilberman S, Rafii DC, Giunta J. Pembrolizumab-induced adrenal insufficiency presenting eight months after cessation of treatment. Cureus. 2023, 15:e41049. 10.7759\/cureus.41049","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28393","article-title":"Adverse endocrine-related effects of pembrolizumab precipitating severe hyponatremia","volume":"14","author":"Baldawi MB","year":"2022","unstructured":"Baldawi MB, Dhami B, Gosai J, Al-Khafaji RH. Adverse endocrine-related effects of pembrolizumab precipitating severe hyponatremia. Cureus. 2022, 14:e28393. 10.7759\/cureus.28393","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52235","article-title":"Pembrolizumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency","volume":"16","author":"Alfares K","year":"2024","unstructured":"Alfares K, Han HJ. Pembrolizumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency. Cureus. 2024, 16:e52235. 10.7759\/cureus.52235","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein SR","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, et al.. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016, 101:364-89. 10.1210\/jc.2015-1710","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2023.11.003","article-title":"Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects","volume":"50","author":"Martella S","year":"2023","unstructured":"Martella S, Lucas M, Porcu M, et al.. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects. Semin Oncol. 2023, 50:144-8. 10.1053\/j.seminoncol.2023.11.003","journal-title":"Semin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/295455-immune-checkpoint-inhibitors-and-endocrine-disruption-a-case-of-hyponatremia-and-adrenal-insufficiency","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:48:48Z","timestamp":1727182128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/295455-immune-checkpoint-inhibitors-and-endocrine-disruption-a-case-of-hyponatremia-and-adrenal-insufficiency"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.70089","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}